Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort.

Adult Antibodies, Monoclonal / adverse effects Antibodies, Monoclonal, Humanized Cohort Studies Conjunctivitis / chemically induced Dermatitis, Atopic / diagnosis Dose-Response Relationship, Drug Drug Administration Schedule Eosinophilia / chemically induced Female France Humans Injections, Subcutaneous Kaplan-Meier Estimate Male Patient Safety / statistics & numerical data Proportional Hazards Models Retrospective Studies Risk Assessment Severity of Illness Index

adults atopic dermatitis biotherapy conjunctivitis dupilumab eosinophilia

Journal

Journal of the American Academy of Dermatology

ISSN: 1097-6787

Titre abrégé: J Am Acad Dermatol

Pays: United States

ID NLM: 7907132

Informations de publication

Date de publication:
Jul 2019

Historique:

received: 30 10 2018

revised: 17 02 2019

accepted: 22 02 2019

pubmed: 3 3 2019

medline: 26 11 2019

entrez: 3 3 2019

Statut: ppublish

Résumé

Dupilumab is the first biologic available to treat atopic dermatitis (AD). Its effectiveness and safety were demonstrated in clinical trials. We sought to assess the effectiveness and safety of dupilumab in adults with AD in a real-life French multicenter retrospective cohort. We included patients treated during March 2017-April 2018. Efficacy outcomes, including Scoring Atopic Dermatitis (SCORAD) and Eczema Area and Severity Index (EASI) scores, were collected at baseline and 3 months when available. Adverse events (AEs) were recorded at follow-up. We included 241 patients. The median ± interquartile range (IQR) follow-up time was 3.8 ± 3.7 months. A ≥75% improvement in SCORAD was achieved in 27 of 163 (16.6%) patients, and a ≥75% improvement in EASI was achieved in 40 of 82 (48.8%) patients. The median SCORAD and EASI scores at 3 months were significantly lower than those at baseline (SCORAD ± IQR, 25 ± 21 vs 56 ± 27.4, P < 10 No control group, missing data. This real-life study demonstrated a similar dupilumab effectiveness as that seen in clinical trials, but it also revealed a higher frequency of conjunctivitis and eosinophilia.

Sections du résumé

BACKGROUND BACKGROUND

Dupilumab is the first biologic available to treat atopic dermatitis (AD). Its effectiveness and safety were demonstrated in clinical trials.

OBJECTIVE OBJECTIVE

We sought to assess the effectiveness and safety of dupilumab in adults with AD in a real-life French multicenter retrospective cohort.

METHODS METHODS

We included patients treated during March 2017-April 2018. Efficacy outcomes, including Scoring Atopic Dermatitis (SCORAD) and Eczema Area and Severity Index (EASI) scores, were collected at baseline and 3 months when available. Adverse events (AEs) were recorded at follow-up.

RESULTS RESULTS

We included 241 patients. The median ± interquartile range (IQR) follow-up time was 3.8 ± 3.7 months. A ≥75% improvement in SCORAD was achieved in 27 of 163 (16.6%) patients, and a ≥75% improvement in EASI was achieved in 40 of 82 (48.8%) patients. The median SCORAD and EASI scores at 3 months were significantly lower than those at baseline (SCORAD ± IQR, 25 ± 21 vs 56 ± 27.4, P < 10

LIMITATIONS CONCLUSIONS

No control group, missing data.

CONCLUSION CONCLUSIONS

This real-life study demonstrated a similar dupilumab effectiveness as that seen in clinical trials, but it also revealed a higher frequency of conjunctivitis and eosinophilia.

Identifiants

DOI: 10.1016/j.jaad.2019.02.053 PMID: 30825533

pubmed: 30825533

pii: S0190-9622(19)30345-7

doi: 10.1016/j.jaad.2019.02.053

pii:

doi:

Substances chimiques

Antibodies, Monoclonal 0

Antibodies, Monoclonal, Humanized 0

dupilumab 420K487FSG

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

Pagination

143-151